Top-News

Pharming Group Aktie News

Aktie
WKN:  A1H65A ISIN:  NL0010391025 US-Symbol:  PHGUF Branche:  Biotechnologie Land:  Niederlande
1,392 €
+0,004 €
+0,29%
08:17:20 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,02 Mrd. €
Streubesitz
78,95%
KGV
-49,08
Index-Zuordnung
-

Pharming Group News

08.12.25 - GlobeNewswire
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
Leiden, the  Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the ...
06.11.25 - GlobeNewswire
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024 RUCONEST® third quarter revenu e increased by 29% to US$82.2 million, ...
30.10.25 - GlobeNewswire
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Leiden, the  Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will ...
23.10.25 - GlobeNewswire
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Leiden, the Netherlands, October 23, 2025:  Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) ...
01.10.25 - GlobeNewswire
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency ...
03.09.25 - GlobeNewswire
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Leiden, the  Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will ...
20.08.25 - EQS
Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
Original-​Research: Pharming Group NV - from First Berlin Equity Research GmbH 20.08.2025 / 16:37 CET/CEST Dissemination of a Research, transmitted by EQS News - a service ...
04.08.25 - GlobeNewswire
Pharming Group to participate in August investor conference
Leiden, the  Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate ...
31.07.25 - GlobeNewswire
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth ...
17.07.25 - GlobeNewswire
Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31
Leiden, the Netherlands, July 17, 2025:  Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) ...
28.05.25 - GlobeNewswire
Pharming Group to participate in June investor conferences
Leiden, the  Netherlands, May 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in ...
08.05.25 - GlobeNewswire
Pharming Group reports first quarter 2025 financial results and provides business update
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to ...
24.04.25 - GlobeNewswire
Pharming Group to report first quarter 2025 financial results on May 8
Leiden, the Netherlands, April 24, 2025:  Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first ...
23.04.25 - GlobeNewswire
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years ...
28.03.25 - GlobeNewswire
Pharming Group to participate in April investor conferences
Leiden, the  Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate ...
20.03.25 - GlobeNewswire
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Multi-​center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID ...
13.03.25 - GlobeNewswire
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth ...
04.03.25 - GlobeNewswire
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Leiden, the Netherlands, March 4, 2025:  Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the ...
27.02.25 - GlobeNewswire
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Leiden, the Netherlands, February 27, 2025:  Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth ...
21.01.25 - GlobeNewswire
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Leiden, the Netherlands, January 21, 2025:  Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of ...

Newssuche

Videos

newspaper
16.12.25 -4,57%
Technical Trading: DAX Setup mit Kurzfrist Trade
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »